80results about "Ligases" patented technology

The present invention relates to a novel CRS fragment peptide having immune enhancing activity and its use, more specifically, to a novel peptide consisting of the amino acid sequence of SEQ ID NO: 2 and its use as a vaccine adjuvant and a cancer therapeutic agent. The peptide disclosed in the present invention exhibits anti-cancer activity and immune function enhancing activity as the CRS fragment disclosed for the first time in the present specification.

Compounds, proteins, crosslinked proteins, compositions thereof, and methods of making and uses thereof. A compound, which may be an alpha-amino acid, comprises one or more beta-lactam group(s), one or more triazole groups, substituted analogs thereof, or any combination thereof. A protein comprises one or more amino acid residue(s), each residue comprising a beta-lactam group, a triazole group, or a substituted analog thereof. A protein can be made by a recombinant method using one or more compound(s). A cross-linked protein comprises one or more intramolecular crosslink(s) and / or one or more intermolecular crosslink(s). In various examples, a crosslink is formed, e.g., in solution or in vivo, by a proximity enabled beta-lactam ring opening reaction or an acyl transfer reaction between a beta-lactam group or a triazole group and a nucleophilic side-chain group, where both groups are on a single polypeptide or on different polypeptide chains. Crosslinked protein(s) can be used in methods of treatment.

The present disclosure relates to animal models that express human tryptophanyl-tRNA synthetase (hWARS) knock-in. These animal models are highly susceptible to enterovirus infection, including but not limited to EV-D68 and EV-A71 infection. Also disclosed are screening methods and compounds that utilize these animal models.

The present disclosure provides compositions, reagents, and methods for generating capped, circular RNA molecules, circularized RNA molecules, and, in particular, circularized mRNA molecules encoding polypeptides such as therapeutic proteins.

The present invention relates to a method for producing glycolipids in recombinant host cells and to a novel glycolipid obtained by said method as well as nucleic acid molecules used in this method.

The present disclosure relates to a modified polypeptide of glutamine synthetase having enhanced activity and a method of producing L-glutamine using the same. Since production of L-glutamine may be increased by using the novel modified polypeptide without a decrease in a growth rate compared to wild-type strains having glutamine synthetase activity, the modified polypeptide may be widely used for mass production of L-glutamine.

The present invention relates to a microorganism transformed to be capable of producing guanidinoacetic acid (GAA) and containing at least one gene encoding a protein having the function of NADH-dependent dehydrogenase, and a method for the fermentative production of GAA using such a microorganism. The present invention also relates to a method for the fermentative production of creatine.

This invention relates to a plant E3 ubiquitin ligase (termed DA2) which acts synergistically with DA1 to control seed and organ size. Methods of increasing plant yield are provided that comprise reducing the expression or activity of DA2 in a plant that is deficient in DA1 expression or activity. Plants with increased yield and methods of producing such plants are also provided.

To provide an improved process of preparing MRNA-loaded lipid nanoparticles.SOLUTION: The present invention provides an improved method for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a method of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA. In particular, encapsulating mRNA by combining pre-formed lipid nanoparticles with mRNA results in formed particles that exhibit unexpectedly efficient in vivo delivery of the mRNA and surprisingly potent expression of proteins and / or peptides that the mRNA encodes.SELECTED DRAWING: None

The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and / or an olivetolic acid cyclase (OAC).

The present invention relates to the purification of linear DNA products, which may have nuclease-resistance. The linear DNA products may be double-stranded or single stranded. In addition, the present invention relates to purified linear DNA products, and their uses.

To provide histidyl-tRNA synthetase Fc conjugate. [Solution] The present invention provides a conjugate polypeptide of histidyl-tRNA synthetase and an Fc region (HRS-Fc conjugate), for example, an HRS-Fc fusion polypeptide, a composition comprising the same, and a method of using such conjugates and compositions to treat or diagnose various conditions. The HRS-Fc conjugate of the present invention has improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties compared to the corresponding unmodified HRS polypeptide.

Genetically engineered bacteria which express RNAs or proteins that produce ammonia upon decreases in phosphate concentrations are disclosed.

The present application belongs to the field of biosynthesis, and particularly relates to a sclareol synthase variant and a yeast engineering bacterium for producing sclareol. In order to solve the problem of generally low yield of sclareol biosynthesis in the prior art, the present application mutates and optimizes the sclareol synthase, obtains a SsScs mutant containing a G307L mutation, and uses the mutant for sclareol synthesis. Meanwhile, in order to solve the problem of genetic instability existing in the expression of free plasmid in some Saccharomyces cerevisiae strains, the present application constructs a sclareol synthesis pathway in the yeast genome, simultaneously strengthens the acetyl coenzyme A synthesis pathway, the MVA pathway and the sclareol synthesis pathway, and knocks out part of the transcriptional repressor to transform the chassis bacterium for synthesizing sclareol, and the yield is greatly improved compared with the prior art.

The present disclosure provides an amino acid molecule, host cells expressing the amino acid molecule, use of host cells to produce L-arginine, nucleic acid molecules with sequences encoding the amino acid molecule, vectors comprising nucleic acid molecules with sequences encoding the amino acid molecule, methods of producing L-arginine, and methods for increasing L-arginine production by a host cell.

Provided is a genetically engineered strain for producing polylactic acid and a method for producing polylactic acid, which comprises the steps of synthesizing D-lactate dehydrogenase gene, propionyl coenzyme A transferase gene and polyhydroxy fatty acid ester synthase gene into a target gene, double enzymatically cleaving with a vector, purifying, transforming a receptor cell to obtain a recombinant plasmid, extracting the DNA of the recombinant plasmid, introducing it into an engineered strain, extracting and verifying it, and obtaining a genetically engineered cell strain, and then cultivating it in a medium, introducing carbon dioxide into the medium, centrifuging under light conditions, drying and recovering it.The present invention greatly improves the biomass of cyanobacteria by modifying natural cyanobacteria and adopting a high-density fermentation strategy, and the present invention solves the problem that only sugar-derived raw materials are used to produce polylactic acid in the conventional technology.

This application discloses an engineered bacterium producing 3-hydroxypropionic acid, its construction method, and its application. The construction method includes: introducing the MCRC gene and MCRN gene into a host strain, and modifying the promoter P of the FAS1 gene of the host strain. FAS1 Replace with P HXT1 The MCRC gene encodes a polypeptide consisting of amino acids 1-549 of malonyl-CoA reductase from Chloroflexus aurantiacus; the MCRN gene encodes a polypeptide consisting of a mutant N940V / K1106W / S1114R consisting of amino acids 550-1219 of malonyl-CoA reductase from Chloroflexus aurantiacus; and the host strain is selected from any of the Saccharomyces cerevisiae species.

Recombinant cells and methods for producing methyl ketones, such as medium-chain methyl ketones. The recombinant cells include recombinant acyl-ACP thioesterase genes, recombinant β-ketoacyl-CoA thioesterase genes, and recombinant acyl-CoA synthetase genes, in addition to other modifications. The methods include culturing the recombinant cells to produce the methyl ketones and isolating the produced methyl ketones.

The present application provides a recombinant E. coli for synthesizing heme and derivatives thereof, wherein the recombinant E. coli is knocked out of genes such as pyruvate oxidase poxB, pyruvate formate-lyase pflB and protoporphyrinogen peroxidase yfeX, and meanwhile, the genes such as phosphopyruvate carboxylase ppc, glycerol transporter glpF and 3-phosphoglycerate dehydrogenase glpD are enhanced, and the genes such as 5-aminovaleryl-CoA synthase hemA and ferrous chelatase hemH are introduced, so that the recombinant E. coli can synthesize heme and derivatives thereof by using glycerol as a raw material, and has application prospects in the field of biological manufacturing.

Provided herein are compositions, kits, systems, and methods employing single-stranded end-preserving adaptors. Such single-stranded adaptors are attached to DNA duplex molecules while preserving original 5′ or 3′ single-strand protruding ends (e.g., present in cell-free DNA) by attaching such adapters to 3′ ends the DNA duplex molecules using a single strand ligase that has step 3 ligase activity, but not step 2 adenylyl transfer activity, and attaching such adapters to 5′ ends of the DNA duplex molecules using a ligase enzyme (e.g., a circligase), thereby forming loop-like structures on one or each end of the DNA duplex molecules. In further embodiments, the loop-like structures are cleaved (e.g., by an endonuclease) as the single-stranded adapters have a cleavable portion, thereby generating a two-part adapter on one or both ends of the DNA duplex molecules that preserves the initial 5′ or 3′ single-strand protruding ends, along with any methylation present.

Dual vector systems, and mammalian host cells comprising them, for the expression of multi chain molecules are provided where each vector employs a different promoter driving the expression of a selectable marker. The mammalian host cells can be used for producing a recombinant protein of interest in a mammalian cell culture.

The application belongs to the field of biological medicine and virus infection, and particularly relates to an inhibitor for limiting virus-mediated cell-cell fusion. The application specifically discloses an inhibitor for limiting cell-cell fusion mediated by pseudorabies virus (PRV), wherein the inhibitor contains MARCH1 protein, and the MARCH1 protein includes a derivative thereof, an isolated nucleic acid molecule, a vector or a host cell containing the MARCH1 protein, and / or a fusion. It is found in the research that MARCH1 significantly inhibits the replication of PRV in the stage of cell-cell fusion, that is, it is found in the application that MARCH1 captures a virus protein complex inducing cell-cell fusion in a trans-Golgi network (TGN), and it is proved that MARCH1 has anti-PRV infection activity.

The application discloses a biotin ligase mutant and application thereof, and belongs to the technical field of genetic engineering. The biotin ligase mutant is prepared by performing multiple mutations on 10 amino acids with a binding force action site which are screened through biotin ligase and substrate molecule docking. On this basis, the biotin ligase mutant is connected to Escherichia coli by using a homologous recombination technology, and a series of Escherichia coli recombinant bacteria with high biotin yield are obtained. The biotin yield of the recombinant bacteria reaches 0.873 mg / L after 24 h fermentation.

This invention belongs to the field of biosynthesis, specifically relating to a variant of lysine pyrophosphate diol synthase and the constructed engineered yeast strain for perillaldehyde synthesis. To address the generally low yield of perillaldehyde biosynthesis in existing technologies, this invention mutates and optimizes the lysine pyrophosphate diol synthase to obtain an SsLPPs mutant containing the G379M mutation, which is then used for perillaldehyde synthesis. Simultaneously, to address the genetic instability issues associated with free plasmid expression in some Saccharomyces cerevisiae strains, this invention constructs a perillaldehyde synthesis pathway within the yeast genome. Furthermore, by enhancing the acetyl-CoA synthesis pathway, the MVA pathway, and the perillaldehyde synthesis pathway, and by knocking out some transcriptional repressors, the substrate strain synthesizing perillaldehyde is modified, resulting in a significantly increased yield compared to existing technologies.

The present disclosure relates to genetically engineered bacteria for producing D-pantothenic acid, a construction method thereof, and application of the genetically engineered bacteria in preparation of the D-pantothenic acid through microbial fermentation. Mainly, (1) carbon flux is further directed toward the synthesis of the D-pantothenic acid by increasing the copy number of key genes in the synthesis pathway of pantothenic acid in an Escherichia coli (E. Coli) organism; and (2) in order to further enhance the carbon flux to direct toward the synthesis of the D-pantothenic acid, glycolysis front-end genes are activated by weakening a nitrogen limitation-negative regulatory transcription factor to drive the carbon flow, phosphoenolpyruvic acid is saved, the central carbon flow entering TCA is reduced, and a plasma-free and antibiotic-free genetically engineered bacterium strain for producing D-pantothenic acid is obtained. Finally, D-pantothenic acid shake flask titer is increased by 87.2% compared with an original strain, which reaches 5.43 g / L; and fermentation is performed with a 5 L fermentation tank for 84 hours, and the yield of the D-pantothenic acid can reach 94.2 g / L.

The present invention relates to a recombinant vector for expression of a target protein or target gene containing a glutamine synthetase split fragment, and a method for selection of a cell line expressing high levels of a recombinant protein using same. According to the present invention, the efficiency of selecting cell lines for biopharmaceutical production dramatically increases,, and it can be used free from stability problems because it is an improvement on the conventionally used selectable marker GS (glutamine synthetase).

The disclosure relates to recombinant host cells including strain modifications effective to improve titer, yield and / or productivity of fatty acid derivatives. The disclosure further relates to cell cultures including the recombinant host cells for the fermentative production of fatty acid derivatives and compositions thereof.

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and / or clearance in tissues, receptor uptake and / or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and / or modulation of a cell's status, function, and / or activity.

The invention belongs to the field of biosynthesis, and in particular relates to an improved variant of libdanenediol pyrophosphate synthase and engineered yeast for producing sclareol. In order to solve the problem that in the prior art, the sclareol biosynthesis yield is generally low, LsLPPs mutant containing N674L mutation is obtained by performing mutation and optimization on LsLPPs pyrophosphate synthase, and the mutant is used for sclareol synthesis. Meanwhile, in order to solve the problem of genetic instability caused by free plasmid expression of part of saccharomyces cerevisiae strains, a sclareol synthesis pathway is constructed in a yeast genome, and meanwhile, an acetyl coenzyme A synthesis pathway, an MVA pathway and a sclareol synthesis pathway are enhanced; and the chassis bacteria for synthesizing sclareol are modified in a manner of knocking out part of transcription inhibition factors, so that the yield is greatly improved compared with the prior art.

The present invention relates to a fragmented GRS polypeptide and a variant thereof, and a use thereof and, more specifically, to: an isolated polypeptide consisting of 8 to 170 consecutive amino acids including amino acids 531 to 538 in the amino acid sequence represented by SEQ ID NO: 1 or a polypeptide consisting of a variant having a sequence homology of 80% or more with the polypeptide; a fusion protein and a complex comprising the polypeptide; a polynucleotide coding for the polypeptide; and a use thereof for the prevention and treatment of neoplastic diseases, the detection of cancer cells, imaging, and drug delivery.